C&L: John Rowley named CEO at DNA Bioscience

DNA Bioscience has appointed John Rowley to the new role of CEO. Rowley's past experience includes working for International SOS, Diageo and GlaxoSmithKline in a variety of senior international management positions.

Guava Technologies has elected Lawrence F. Bruder to the position of president and COO. Bruder, who joined Guava Technologies in 2004, previously held the title of vice president, corporate development and worldwide marketing.

FzioMed has appointed John S. Krelle as president and COO. He most recently worked for Zimmer.

Andrew Maslan has been named CFO of Cytomedix, succeeding Bill Allender. Prior to joining Cytomedix, he served as controller for BioReliance.

Calypte Biomedical has promoted Dr. Ronald W. Mink to the position of chief science officer, replacing Dr. Toby Gottfried who retired in June.

Prof. Santa Jeremy Ono has been hired as chief scientific officer of iCo Therapeutics. Prof. Ono currently serves as GlaxoSmithKline Professor of Biomedical Sciences, University College, University of London, and Chair of Immunology, UCL-Institute of Ophthalmology, Moorfields Eye Hospital.

Human Genome Sciences has named Barry A. Labinger executive vice president and chief commercial officer. Labinger will join Human Genome Sciences from 3M Pharmaceuticals, where he serves as division vice president.

DeCODE genetics has named Daniel L. Hartman, MD, as senior vice president of product development. Also joining deCODE's drug development team are Dr. David Hermann, who for the past four years has served as director of pharmacometrics at Pfizer Global Research and Development, and Dr. Peter Van Ess, previously global clinical pharmacokinetics and pharmacodynamics program leader at Pfizer.

MorphoSys has appointed Dr. Robert Friesen as director of pre-clinical development and Dr. Bernhard Erning as director of treasury and corporate development.

QuatRx Pharmaceuticals has named Jeffery M. Brinza to the position of general counsel. Brinza most recently served as a partner at Brinza & Associates.

Patrick Scrivens has been named as an advisor to Stellar Pharmaceuticals. He is the founder, chairman and CEO of Advisory Associates of McLean, Virginia, a merchant banking firm that provides financial management and strategic business advisory services.

Intrac and its wholly-owned subsidiary, Innovative Drug Delivery Systems, appointed William Peters, MD, PhD, to its board of directors.

Nuvelo has appointed Kimberly Popovits to its board of directors. Ms. Popovits currently serves as president and COO of Genomic Health.

Charles J. Homcy, MD, has been named to Geron's board of directors.

Jorge Leon, PhD, has joined Orion Genomics' board of directors.

Stem Cell Therapeutics has named Dr. James M. DeMesa, MD, MBA, as a member of its board of directors.

Barrier Therapeutics has named Carol Raphael to its board of directors.

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.